Frey NV, Porter DL. Graft-versus-host disease after donor leukocyte infusions: presentation and management. Best Pract Res Clin Haematol 2008;21(2):205-222.
Kelli PA, Geoffrey RH, Bruce RB. Chronic graft-versus-host disease: Biological insights from preclinical and clinical studies. Blood 2017;129:13-21.
Khayamzadeh M, Kavianibet H. A review on therapeutic management for oral chronic graft-versus-host disease. J Contemp Med Sci 2020;6(5):193–202.
Kim YJ, Lee GH, Kwong BY, Martires KJ. Evidence-based, skin-directed treatments for cutaneous chronic graft-versus-host disease. Cureus 2019;11(12):e6462.
Kok LMC, Bungener L, de Bock GH, Biswana A, van der Wal G, van Imhoff GW, et al. Risk factors associated with the development of moderate to severe chronic graft-versus-host disease after non-myeloablative conditioning allogeneic stem cell transplantation in patients with AML or MDS. Hum Cell 2020;33(1):243-251.
Liu QF, Luo XD, Ning J, Xu D, Fan ZP, Sun J, et al. Association between acute graft versus host disease and lung injury after allogeneic haematopoietic stem cell transplantation. Haematology 2009;14(2):63-72.
Matin R. Guidelines for diagnosis and management of cutaneous graft-versus-host disease. July 2019. Available at: http://nssg.oxford-haematology.org.uk/bmt/gvhd/B-2-7c-diagnosis-and-management-cutaneous-gvhd.pdf. Accessed: 9 February 2020.
McLornan D, Szydlo R, Koster L, Chalandon Y, Robin M, Wolschke C, et al. Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: A retrospective study by the chronic malignancies working party of the European society for blood and marrow transplantation. Biol Blood Marrow Transplant 2019;25(11):
Meyer KC. Diagnosis and management of bronchiolitis obliterans syndrome following lung or haematopoietic cell transplantation. Expert Rev Respir Med 2016;10(6):599-602.
Murray J, Stringer J, Hutt D. Chapter 11Graft-Versus-Host Disease (GvHD). In: Kenyon M, Babic A (editors). The European Blood and Marrow Transplantation Textbook for Nurses: Under the Auspices of EBMT [Internet]. Published online: 22 November 2017. Available at: https://www.ncbi.nlm.nih.gov/books/NBK543657/. Accessed: 9 February 2020.
Neumann J. Nursing challenges caring for bone marrow transplantation patients with graft versus host disease. Haematol Oncol Stem Cell Ther 2017;10(4):192-194.
Neumann JL, Alousi AM. Nursing challenges caring for HSCT patients with GVHD. Biol Blood Marrow Transplant 2019;25:S290-S442. Abstract 664.
NHS England. Specialised Services Clinical Reference Group for Blood and Marrow Transplantation. Clinical Commissioning Policy: Treatments for Graft versus Host Disease (GvHD) following Haematopoietic Stem Cell Transplantation. NHS England: 16069/P. March 2017. Available at: https://www.england.nhs.uk/wp-content/uploads/2017/03/gvhd-heamatopoietic-stem-cell.pdf. Accessed: 9 February 2020.
NHS Rapid policy statement. Reference 001559. Ruxolitinib for chronic graft versus host Disease (RPS 2010). 11 November 2020. Version 1. Available at: https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/11/C0733-2010RU-PostCP-November-2020.pdf. Accessed: 9 February 2020. Strong-Rodrigues K, Oliveira-Ribeiro C, de Abreu Fiuza Gomes S, Knobler R. Cutaneous graft-versus-host disease: Diagnosis and treatment. Am J Clin Dermatol 2018;19(1):33-50.
Oncolink Penn Medicine. Graft Versus Host Disease: A Learning Module for Nurses.
University Hospital Southampton NHS Foundation Trust. Patient information factsheet: Psoralen ultraviolet light A (PUVA) treatment. Version 2. 2019. Available at: https://www.uhs.nhs.uk/Media/UHS-website-2019/Patientinformation/Skin/PUVA-treatment-patient-information.pdf. Accessed: 10 February 2021.
Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H, et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukaemia patients after allogeneic hematopoietic stem cell transplantation. Blood 2012;119(14):3256-3262.